BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aims
Post# of 122
(Total Views: 185)
Posted On: 04/25/2023 4:07:43 PM
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aims to Complement its NanoAb Core Focus with Comprehensive Contract Development and Manufacturing Organization Services
- BiondVax intends to expand its contract development and manufacturing organization (“CDMO”) offering as it continues the primary focus on its NanoAb pipeline development
- The CDMO services include aseptic fill and finish, upstream and downstream process development, as well as analytical model development and analytical testing
- This is made possible by BiondVax’s state-of-the-art assets in Jerusalem, Israel, including GMP-ready production clean rooms, fermentors, WFI, analytic tools, media, and buffer preparations
- With a combined 17 years of experience in recombinant protein process development from bench to Phase 3, BiondVax’s boutique CDMO service is well positioned to meet client needs
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, primarily for treatment of infectious and autoimmune diseases, aims to complement its core focus, nanosized sized antibody (NanoAb) pipeline development, with a comprehensive CDMO (contract development and manufacturing organization) offering. With significant experience including developing its previous flu vaccine candidate, BiondVax intends to share its expertise, human resources, and facilities, with pharma companies, to develop and manufacture their drug candidates for preclinical use as well as clinical testing (https://nnw.fm/mZ6zX ).
BiondVax’s CDMO services cover aseptic fill and finish, upstream and downstream process development, as well as analytical model development, among others. In addition, the company also offers comprehensive CDMO services geared towards supporting pilot, clinical, and process development stages, alternative protein food tech, pharmaceutical and biotech companies.
This offering is intended to generate additional revenues for BiondVax and is made possible by the company’s growing assets ranging from GMP-ready production clean rooms to a 250mL Ambr® Fermentor, and 2L and 5L fermentors for upstream process optimization. The company also offers Water For Injection (“WFI”), 30L, and 300L fermentors for upstream GMP production in addition to analytic tools, media, and buffer preparations.
Under the leadership of Amir Reichman, CEO, Dr. Tamar Ben-Yedidia, CSO and Elad Mark, COO, pharma companies can engage with confidence the Israel-based CDMO, knowing that everything is handled expertly by industry-leading professionals. With 17 years of experience in recombinant protein process development from bench to Phase 3, companies interested in BiondVax’s CDMO services are assured that their processes will be professionally executed, and their outcomes produce with scientific rigor.
BiondVax’s management is optimistic generating revenues and new scientific affiliations through its CDMO offering while it continues to deliver on its core focus, an innovative NanoAb pipeline development for treatment of large market disorders in both infectious and autoimmune diseases.
For more information about BiondVax’s CDMO services, please visit www.BiondVax.com/CDMO.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- BiondVax intends to expand its contract development and manufacturing organization (“CDMO”) offering as it continues the primary focus on its NanoAb pipeline development
- The CDMO services include aseptic fill and finish, upstream and downstream process development, as well as analytical model development and analytical testing
- This is made possible by BiondVax’s state-of-the-art assets in Jerusalem, Israel, including GMP-ready production clean rooms, fermentors, WFI, analytic tools, media, and buffer preparations
- With a combined 17 years of experience in recombinant protein process development from bench to Phase 3, BiondVax’s boutique CDMO service is well positioned to meet client needs
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, primarily for treatment of infectious and autoimmune diseases, aims to complement its core focus, nanosized sized antibody (NanoAb) pipeline development, with a comprehensive CDMO (contract development and manufacturing organization) offering. With significant experience including developing its previous flu vaccine candidate, BiondVax intends to share its expertise, human resources, and facilities, with pharma companies, to develop and manufacture their drug candidates for preclinical use as well as clinical testing (https://nnw.fm/mZ6zX ).
BiondVax’s CDMO services cover aseptic fill and finish, upstream and downstream process development, as well as analytical model development, among others. In addition, the company also offers comprehensive CDMO services geared towards supporting pilot, clinical, and process development stages, alternative protein food tech, pharmaceutical and biotech companies.
This offering is intended to generate additional revenues for BiondVax and is made possible by the company’s growing assets ranging from GMP-ready production clean rooms to a 250mL Ambr® Fermentor, and 2L and 5L fermentors for upstream process optimization. The company also offers Water For Injection (“WFI”), 30L, and 300L fermentors for upstream GMP production in addition to analytic tools, media, and buffer preparations.
Under the leadership of Amir Reichman, CEO, Dr. Tamar Ben-Yedidia, CSO and Elad Mark, COO, pharma companies can engage with confidence the Israel-based CDMO, knowing that everything is handled expertly by industry-leading professionals. With 17 years of experience in recombinant protein process development from bench to Phase 3, companies interested in BiondVax’s CDMO services are assured that their processes will be professionally executed, and their outcomes produce with scientific rigor.
BiondVax’s management is optimistic generating revenues and new scientific affiliations through its CDMO offering while it continues to deliver on its core focus, an innovative NanoAb pipeline development for treatment of large market disorders in both infectious and autoimmune diseases.
For more information about BiondVax’s CDMO services, please visit www.BiondVax.com/CDMO.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)